Tiffany Tanaka

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Mentored Career Development Program
    NIH KL2TR001444Aug 13, 2015 - Apr 30, 2025
    Role: Grant Recipient 2019-2022
    Description: Predictive Gene Expression Profiling and Immunophenotypes in Myelodysplastic Syndromes
    UC San Diego Clinical and Translational Research Institute
    NIH UL1TR001442Aug 13, 2015 - Apr 30, 2025
    Role: Grant Recipient 2018
    Description: Understanding how clonal hematopoiesis mediates cardiovascular risk through single cell transcriptome, epigenome and targeted exome analysis of clonal immune cells

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. PMID: 38394770.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. CML and the WHO: Why? J Clin Oncol. 2024 Mar 20; 42(9):984-986. Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. PMID: 38086008.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. PMID: 37703506; PMCID: PMC10617926.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    4. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 05 20; 41(15):2815-2826. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. PMID: 36888930; PMCID: PMC10414740.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    5. Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing. Front Oncol. 2022; 12:915629. Ferrari V, Tarke A, Fields H, Tanaka TN, Searles S, Zanetti M. PMID: 35992887; PMCID: PMC9389224.
      View in: PubMed   Mentions:
    6. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Immunity. 2022 08 09; 55(8):1386-1401.e10. Cobo I, Tanaka TN, Chandra Mangalhara K, Lana A, Yeang C, Han C, Schlachetzki J, Challcombe J, Fixsen BR, Sakai M, Li RZ, Fields H, Mokry M, Tsai RG, Bejar R, Prange K, de Winther M, Shadel GS, Glass CK. PMID: 35931086; PMCID: PMC9718507.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    7. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Curr Opin Hematol. 2022 01 01; 29(1):1-7. Cobo I, Tanaka T, Glass CK, Yeang C. PMID: 34654019; PMCID: PMC8639635.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    8. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome. Cytotherapy. 2021 03; 23(3):236-241. Tanaka TN, Ferrari V, Tarke A, Fields H, Ferrari L, Ferrari F, McCarthy CL, Sanchez AP, Vitiello A, Lane TA, Bejar R. PMID: 33279399.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    9. In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. Cytotherapy. 2021 04; 23(4):320-328. Ferrari V, Tarke A, Fields H, Ferrari L, Conley T, Ferrari F, Kosaloglu-Yalçin Z, Sette A, Peters B, McCarthy CL, Bashey A, Tzachanis D, Ball ED, Tanaka TN, Bejar R, Lane TA, Vitiello A. PMID: 33262074.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    10. 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells. Mol Cancer Res. 2021 03; 19(3):451-464. Reilly BM, Luger T, Park S, Lio CJ, González-Avalos E, Wheeler EC, Lee M, Williamson L, Tanaka T, Diep D, Zhang K, Huang Y, Rao A, Bejar R. PMID: 33172974; PMCID: PMC7925369.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Adv. 2019 10 08; 3(19):2845-2858. Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R. PMID: 31582393; PMCID: PMC6784525.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    12. Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region. Br J Haematol. 2019 08; 186(4):509. Wang HY, Tanaka TN, Dell'Aquila M. PMID: 31134617.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019 04 23; 3(8):1197-1210. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. PMID: 30971397; PMCID: PMC6482353.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    14. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019 05 20; 37(15):1336-1351. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. PMID: 30969847.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    15. MDS overlap disorders and diagnostic boundaries. Blood. 2019 03 07; 133(10):1086-1095. Tanaka TN, Bejar R. PMID: 30670443.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    16. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):346-352.e5. Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED. PMID: 29572158.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    17. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):613-620. Sallman DA, Tanaka TN, List A, Bejar R. PMID: 29025689.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    Tiffany's Networks
    Concepts (88)
    Derived automatically from this person's publications.
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _